Published in Circulation on July 24, 2006
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ (2015) 2.40
Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail (2010) 2.35
Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. Am Heart J (2006) 2.10
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation (2015) 1.96
Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail (2010) 1.93
Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation (2011) 1.78
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med (2013) 1.61
Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res (2014) 1.56
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51
Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. Eur J Heart Fail (2011) 1.51
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail (2012) 1.46
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol (2008) 1.14
Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci (2007) 1.13
A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.11
Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail (2014) 1.07
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail (2013) 1.06
Na+/Ca2+ exchange and Na+/K+-ATPase in the heart. J Physiol (2015) 1.06
Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity-matched study of multimorbidity in chronic heart failure. Int J Cardiol (2009) 1.01
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol (2011) 0.98
Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. Am J Cardiol (2009) 0.97
Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol (2008) 0.96
Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol (2015) 0.95
Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol (2015) 0.95
Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail (2009) 0.94
Heart failure with preserved ejection fraction. Glob Cardiol Sci Pract (2012) 0.94
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2012) 0.94
Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93
The underuse of digoxin in heart failure, and approaches to appropriate use. CMAJ (2007) 0.92
Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure. Clin Res Cardiol (2009) 0.91
Chronic heart failure in older adults. Med Clin North Am (2011) 0.90
Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study. PLoS One (2016) 0.89
Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol (2009) 0.89
Office management of patients with diastolic heart failure. CMAJ (2009) 0.88
Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. Int J Cardiol (2011) 0.86
Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc (2011) 0.85
Patients with left ventricular ejection fraction greater than 58 % have fewer incidences of future acute decompensated heart failure admission and all-cause mortality. Heart Vessels (2015) 0.85
Low-Dose Digoxin and Reduction in Mortality and Morbidity in Heart Failure. Int J Cardiol (2009) 0.84
Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med (2013) 0.84
DEFEAT heart failure: assessment and management of heart failure in nursing homes made easy. J Am Med Dir Assoc (2008) 0.84
Heart failure with preserved ejection fraction. Pflugers Arch (2014) 0.82
Prolonged electrocardiogram QRS duration independently predicts long-term mortality in patients hospitalized for heart failure with preserved systolic function. J Card Fail (2009) 0.81
Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? Cardiol Res Pract (2013) 0.81
Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania. Clin Interv Aging (2015) 0.81
Targeting heart failure with preserved ejection fraction: current status and future prospects. Vasc Health Risk Manag (2016) 0.80
Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. Curr Heart Fail Rep (2013) 0.80
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.79
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Curr Diab Rep (2016) 0.79
Pharmacological treatment of chronic heart failure. Heart Fail Rev (2006) 0.79
Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study). Am J Cardiol (2010) 0.79
Association between coronary artery calcification and left ventricular diastolic dysfunction in elderly people. Heart Vessels (2015) 0.78
Fasudil improves short-term echocardiographic parameters of diastolic function in patients with type 2 diabetes with preserved left ventricular ejection fraction: a pilot study. Heart Vessels (2014) 0.78
Necessary cautions when considering digoxin in heart failure. CMAJ (2007) 0.78
Ouabain attenuates cardiotoxicity induced by other cardiac steroids. Br J Pharmacol (2010) 0.78
Heart failure with preserved ejection fraction. J Geriatr Cardiol (2013) 0.78
Advances in diastolic heart failure. World J Cardiol (2010) 0.78
Recent advances in treatment of heart failure. F1000Res (2015) 0.78
Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother (2017) 0.78
The causes, consequences, and treatment of left or right heart failure. Vasc Health Risk Manag (2011) 0.77
Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. Int J Cardiol (2014) 0.77
Time-Dependent Regional Myocardial Strains in Patients with Heart Failure with a Preserved Ejection Fraction. Biomed Res Int (2016) 0.77
Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. Curr Cardiol Rev (2015) 0.77
[Diastolic heart failure: heart failure with preserved ejection fraction]. Z Gerontol Geriatr (2013) 0.77
Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". World J Cardiol (2015) 0.76
Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction. ESC Heart Fail (2015) 0.75
Treatment of heart failure with normal ejection fraction. Curr Treat Options Cardiovasc Med (2011) 0.75
TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF? Glob Cardiol Sci Pract (2013) 0.75
Does digoxin therapy affect outcome in patients with diastolic heart failure? Nat Clin Pract Cardiovasc Med (2007) 0.75
Heart failure. BMJ Clin Evid (2011) 0.75
Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data. Int J Cardiol (2010) 0.75
Heart failure. BMJ Clin Evid (2010) 0.75
Heart failure with a normal ejection fraction: treatments for a complex syndrome? Curr Treat Options Cardiovasc Med (2012) 0.75
A man awaiting a double transplant. BMJ Case Rep (2012) 0.75
Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. Am J Cardiol (2014) 0.75
DEFEAT - Heart Failure: a guide to management of geriatric heart failure by generalist physicians. Minerva Med (2009) 0.75
Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review. Br J Clin Pharmacol (2011) 0.75
Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians. Hosp Pharm (2015) 0.75
Midlife blood pressure predicts future diastolic dysfunction independently of blood pressure. Heart (2016) 0.75
[Digitalis and theophylline: old and superfluous?]. Z Gerontol Geriatr (2013) 0.75
Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol (2017) 0.75
Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med (2017) 0.75
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med (1997) 10.68
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med (2004) 8.12
Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol (1999) 5.43
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA (2002) 4.06
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation (2002) 2.78
Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials (1996) 2.37
Determination of vital status at the end of the DIG trial. Control Clin Trials (2003) 2.28
Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation (2001) 2.05
Digoxin in the management of cardiovascular disorders. Circulation (2004) 1.76
Association of diastolic dysfunction and outcomes in ambulatory older adults with chronic heart failure. J Gerontol A Biol Sci Med Sci (2005) 1.64
Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med (1985) 1.60
Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm (2005) 1.59
Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation (1989) 1.28
Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med (1983) 1.27
Digoxin. A neurohormonal modulator in heart failure? Circulation (1991) 1.25
Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J (2002) 1.18
Functional significance of Na- K-ATPase in the kidney: effects of ouabain inhibition. Am J Physiol (1972) 1.16
Pressure-diameter relations during early diastole in dogs. Incompatibility with the concept of passive left ventricular filling. Circ Res (1981) 0.95
Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role? Prog Cardiovasc Dis (1998) 0.89
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA (2005) 6.32
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol (2009) 5.76
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant (2013) 4.60
Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA (2007) 4.59
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA (2006) 4.30
Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation (2003) 4.25
Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol (2004) 4.14
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14
Electronic health records and quality of diabetes care. N Engl J Med (2011) 4.00
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol (2007) 3.92
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation (2010) 3.63
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 3.39
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J (2004) 3.37
The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 3.36
Systolic and diastolic mechanics in stress cardiomyopathy. Circulation (2014) 3.36
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 3.26
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24
Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol (2011) 3.19
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med (2010) 3.05
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol (2012) 3.03
Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation (2003) 3.01
Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med (2007) 2.95
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
The pathophysiology of acute heart failure--is it all about fluid accumulation? Am Heart J (2008) 2.84
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation (2013) 2.82
Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation (2010) 2.77
Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol (2008) 2.75
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J (2008) 2.71
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol (2005) 2.71
Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol (2004) 2.69
The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant (2012) 2.69
Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail (2008) 2.69
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol (2008) 2.66
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant (2009) 2.49
Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (2002) 2.47
Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol (2008) 2.47
The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail (2002) 2.45
Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA (2009) 2.44
Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med (2008) 2.42
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.42
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39